Quetiapine (mean dosage 62.5 mg/day) was also an effective alternative for improving psychosis in 29 patients unresponsive to or who could not tolerate other atypical antipsychotics (clozapine, risperidone or olanzapine), or those who were noncompliant with blood monitoring. A statistically significant ...
Interim results suggest similar efficacy for quetiapine (600 mg/day), olanzapine (15 mg/day) and risperidone (5 mg/day) in a small, randomised, rater-blinded trial. Furthermore, improvements in overall psychopathology and the positive and negative symptoms of schizophrenia were similar with quetiap...
In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. Quetiapine is not...
The results of a large retrospective cohort study appear to indicate that atypical antipsychotic agents (e.g., clozapine, olanzapine, risperidone, this drug) increase the risk of venous thromboembolism in elderly patients; however, these events seem to be rare. ...
(olanzapine, quetiapine, risperidone, and aripiprazole) that were used most frequently yielded a sample size that was reasonably large enough to avoid CMS cell suppression and that could be included for analysis. Therefore, we included the primary comparator cohort of “Other-AAPs” to provide a ...
The incidence of discontinuation due to adverse reactions for quetiapine-treated and placebo-treated patients was 11.4% and 4.4%, respectively. The adverse reactions leading to discontinuation in 2% or more of patients on SEROQUEL and at a greater incidence than placebo were somnolence (4.1% vs....
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emerg Med. 2004;22(3):181–6. Article PubMed Google Scholar Lindenmayer JP, Brown D, Liu S, Brecher M, Meulien D. The efficacy and tolerability of once-daily ...
In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects. Quetiapine exten...